Hint mode is switched on Switch off

Nurix Therapeutics, ordinary share
NRIX, US67080M1036

Add a stock to WL
Choose all Reset all
Nurix Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

  • Issuer
  • Full borrower / issuer name
    Nurix Therapeutics Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    NRIX
  • Placement
    24.07.2020
  • Lock up period
    180
  • Number of papers
    11,000,000
  • Volume of raised funds
    209 mln USD
  • Placement share
    29.7%
  • Final placement price
    19 USD
  • Price change since placement date
    -100%
  • By capitalization
    703.72 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    NRIX
  • Placement
    05.03.2021
  • Lock up period
    180
  • Number of papers
    4,500,000
  • Volume of raised funds
    139.5 mln USD
  • Placement share
    10.38%
  • Final placement price
    31 USD
  • Price change since placement date
    -100%
  • By capitalization
    1,344.31 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

11/06/2026 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibit 99.1, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Other Events, Financial Statements And Exhibits
06/06/2026 Nurix Therapeutics: Of This Current Report On Form 8k, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
12/01/2026 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
22/10/2025 Nurix Therapeutics: Other Events, Financial Statements And Exhibits
03/09/2025 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibit 99.1, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.